7th Nov 2025 07:00
7 November 2025
MedPal AI plc
(the "Company" or "MedPal AI")
Launch of MedPal.clinic: UK's First AI-Powered, Multimodal Pharmacy Platform
MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence ("AI") company focused on wellness management, is pleased to announce the launch of MedPal.clinic, its retail pharmacy website, marking a significant milestone in the Company's mission to make healthcare accessible and affordable for everyone.
The Directors believe that MedPal.clinic represents a UK-first in digital pharmacy services, combining AI-powered triage with access to qualified Independent Prescribers ("IPs") and General Practitioners ("GPs"), delivered through a multimodal communications platform. Users can access clinical consultations via their preferred communication method, including text messaging and WhatsApp, providing unprecedented flexibility and convenience in accessing primary care services.
Market Opportunity
The MedPal.clinic platform is initially targeting the rapidly expanding UK weight-loss medication market, specifically GLP-1 agonist treatments, which represents a significant revenue opportunity. Recent research indicates that approximately 2.5 million UK adults either currently use or have strong interest in using GLP-1 drugs for weight loss, with private prescription costs averaging £150-£200 per month. This represents a target addressable market exceeding £500 million in monthly revenue within the UK alone.
Revolutionary Healthcare Delivery Model
MedPal.clinic is powered by the Company's integrated, AI-driven healthcare ecosystem operating around the clock from its recently opened distribution centre at Ecotech Business Park, Swaffham. The key advantages of the platform include:
• Zero-cost consultations: The Company's proprietary AI triage system assesses patient needs in seconds, fast-tracking routine medication requests whilst escalating complex cases to qualified IPs and GPs. Advanced AI triage, combined with robotic dispensing automation, has enabled MedPal to eliminate consultation fees entirely, providing free access to IPs and GPs across the UK - a significant differentiator in the market.
• Multimodal access: maximum communication flexibility allowing patients to engage via text, WhatsApp, or other preferred channels.
• Same-day and next-day delivery: Prescriptions dispensed using state-of-the-art robotic technology (Omnicell VBM and BD Rowa VMAX systems) at the Company's automated 24/7 distribution centre, with rapid nationwide delivery.
By combining artificial intelligence, robotic automation, and human clinical expertise, MedPal.clinic eliminates the traditional bottlenecks in patient care: long wait times, geographic and access constraints, and high costs.
Strategic Integration with MedPal Ecosystem
The launch of MedPal.clinic completes the Company's dual-engine business model:
1. AI-driven wellness app: Data aggregation from over 100 wearables and health apps, providing personalised non-clinical insights and lifestyle guidance through the Company's AI wellness coach; and
2. Regulated Distance Selling Pharmacy (DSP): Acquired through the purchase of assets from Universal Pharmacy Limited (as announced on 1 October 2025), operating from the expanded and automated distribution centre (as announced on 22 October 2025).
This highly complementary flywheel drives demand generation through the wellness app whilst fulfilling clinical needs through MedPal.clinic's regulated pharmacy services.
Market Positioning and Partnerships
The traditional pharmacy model presents challenges for users with regard to cost, convenience, and accessibility. MedPal.clinic addresses these through technology-driven efficiency gains and is targetingthe weight-loss medication market which is experiencing rapid growth in the UK and which is forecast to grow to more than a billion pound market opportunity in just the coming years.
MedPal AI's route-to-market partnerships provide access to 11 million+ eligible employees via Epassi UK Limited and free initial access for members of 2,000+ gyms through Independent Gyms Ltd, with revenue share arrangements on post-trial subscriptions. The Company's automated, AI-enhanced infrastructure delivers superior unit economics compared to traditional pharmacy models, enabling competitive pricing whilst maintaining clinical safety and quality standards.
Jason Drummond, Chief Executive Officer of MedPal AI, commented:
"The launch of MedPal.clinic represents the culmination of our strategic vision to democratise healthcare access in the UK. By combining our proprietary AI triage system with advanced robotic dispensing at our Swaffham facility, we have created a platform that eliminates the financial barrier to GP and Independent Prescriber consultations entirely - something no other service has achieved.
"Our multimodal approach, allowing patients to communicate via text, WhatsApp, or their preferred channel, sets a new standard for digital healthcare accessibility. Coupled with same-day delivery and 24/7 availability, MedPal.clinic addresses the fundamental failings of the traditional pharmacy model: cost, convenience, and accessibility.
"With our established partnerships providing access to over 13 million potential users, and the rapidly growing demand for weight-loss medications, we are well-positioned to capture significant market share whilst delivering value to patients across the UK."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company take responsibility for the contents of this announcement.
For further information please visit www.medpalplc.com or contact:
MedPal AI plc via Square1 Consulting
Jason Drummond, Chief Executive Officer
Cairn Financial Advisers LLP +44 20 7213 0880
Louise O'Driscoll/Jo Turner
Clear Capital Markets Limited +44 20 3869 6080
Bob Roberts/ Nick Josh
Square1 Consulting +44 20 7929 5599
David Bick +44 7831 381201
About MedPal AI
MedPal AI is a UK-based digital health company specialising in AI-driven wellness management and regulated online pharmacy services. Its core app aggregates data from over 100 wearables and health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile, offering non-clinical, personalised lifestyle guidance through its AI wellness coach. The Company is also developing conversational AI to provide voice-based, real-time health insights, alerts, and recommendations.
Through its wholly owned subsidiary MedPal Limited, the Company operates a Distance Selling Pharmacy (DSP) licence and a state-of-the-art, AI-powered, automated distribution centre at Ecotech Business Park, Swaffham, capable of dispensing over 100,000 prescriptions per month with 24/7 capability.
MedPal AI has a partnership agreement with Epassi UK Limited, which grants access to the MedPal AI app across Epassi's network of 11M+ employees at major firms like Siemens and Volvo. The Company also has a partnership agreement with Independent Gyms Ltd, providing access to members of over 2,000 gyms across the UK. Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare providers, businesses, and insurers.
Visit our website: www.medpalplc.com
Follow us on social media:
X: @MedPalPlc
LinkedIn: MedPal AI plc
Forward Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
Related Shares:
Medpal AI